Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1050 of 2051 entries
View as:

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Phase: N/A Priority: Normal
NCT ID: NCT00739830 Org: User:
Start: 08/31/08 End: 07/31/12 Due: 07/31/13

A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)

Phase: N/A Priority: Normal
NCT ID: NCT00551629 Org: User:
Start: 05/31/01 End: 03/31/03 Due: 03/31/04

[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)

Phase: N/A Priority: Normal
NCT ID: NCT01385033 Org: User:
Start: 08/19/11 End: 05/15/12 Due: 05/15/13

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)

Phase: N/A Priority: Normal
NCT ID: NCT00725075 Org: User:
Start: 04/10/07 End: 10/24/08 Due: 10/24/09

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

Phase: N/A Priority: Normal
NCT ID: NCT00701389 Org: User:
Start: 11/20/07 End: 04/10/08 Due: 04/10/09

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)

Phase: N/A Priority: Normal
NCT ID: NCT00790205 Org: User:
Start: 12/10/08 End: 03/30/15 Due: 03/30/16

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Phase: N/A Priority: Normal
NCT ID: NCT01304498 Org: User:
Start: 02/23/11 End: 12/20/11 Due: 12/20/12

The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

Phase: N/A Priority: Normal
NCT ID: NCT01937975 Org: User:
Start: 09/06/13 End: 12/17/13 Due: 12/17/14

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Phase: N/A Priority: Normal
NCT ID: NCT01537757 Org: User:
Start: 03/31/12 End: 05/31/12 Due: 05/31/13

Dyskinesia in Parkinson's Disease (Study P04501)

Phase: N/A Priority: Normal
NCT ID: NCT00406029 Org: User:
Start: 11/20/06 End: 11/03/08 Due: 11/03/09

Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00393523 Org: User:
Start: 09/30/06 End: 06/30/08 Due: 06/30/09

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Phase: N/A Priority: Normal
NCT ID: NCT01096667 Org: User:
Start: 05/17/10 End: 02/25/11 Due: 02/25/12

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00975052 Org: User:
Start: 01/31/06 End: 03/31/06 Due: 03/31/07

Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00517309 Org: User:
Start: 12/28/01 End: 06/11/04 Due: 06/11/05

Ezetrol Post-Marketing Study

Phase: N/A Priority: Normal
NCT ID: NCT00753883 Org: User:
Start: 07/31/06 End: - Due: -

To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

Phase: N/A Priority: Normal
NCT ID: NCT00397956 Org: User:
Start: 09/30/04 End: 12/31/05 Due: 12/31/06

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Phase: N/A Priority: Normal
NCT ID: NCT00092547 Org: User:
Start: 10/08/03 End: 06/01/15 Due: 06/01/16

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Phase: N/A Priority: Normal
NCT ID: NCT01678820 Org: User:
Start: 10/10/12 End: 11/01/13 Due: 11/01/14

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Phase: N/A Priority: Normal
NCT ID: NCT05261126 Org: User:
Start: 03/10/22 End: 11/28/22 Due: 11/28/23

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Phase: N/A Priority: Normal
NCT ID: NCT00288431 Org: User:
Start: 02/28/06 End: 07/31/08 Due: 07/31/09

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Phase: N/A Priority: Normal
NCT ID: NCT00401310 Org: User:
Start: 07/31/07 End: 01/31/09 Due: 01/31/10

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Phase: N/A Priority: Normal
NCT ID: NCT06860243 Org: User:
Start: 05/13/25 End: 08/26/25 Due: 08/26/26

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00696826 Org: User:
Start: 04/30/04 End: 05/31/04 Due: 05/31/05

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Phase: N/A Priority: Normal
NCT ID: NCT04634877 Org: User:
Start: 01/10/21 End: 09/15/26 Due: 09/15/27

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Phase: N/A Priority: Normal
NCT ID: NCT05450198 Org: User:
Start: 08/08/22 End: 05/22/24 Due: 05/22/25